Lobbying Governance
| Overall Assessment | Analysis | Score |
|---|---|---|
| Limited |
Sumitomo Pharma provides only limited insight into how it governs its climate-related advocacy. It notes that “we participate in activities of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) … [which] has drawn up an ‘Action Plan for a Low-Carbon Society’ and is promoting reductions in CO2 emissions” and that it collaborates with the FPMAJ subcommittee on HFC reduction, indicating an intention to engage through industry bodies that are broadly aligned with national decarbonisation goals. The company also confirms that it has “a public commitment … to conduct [its] engagement activities in line with the goals of the Paris Agreement,” signalling a high-level pledge to align lobbying with climate objectives. However, the disclosure does not identify any internal mechanism, such as a board committee, executive, or review process, that oversees or monitors whether either its direct advocacy or its participation in trade associations remains consistent with its climate strategy; nor does it describe how potential misalignments would be detected or addressed. As no concrete governance structures, monitoring procedures, or accountability measures are presented beyond the stated commitment, this indicates limited governance of climate-related lobbying alignment.
View Sources
|
D |